"When a pharmaceutical company decides who among us is worthy, and who among us is not, we are no longer living in an ethical, moral society. We are playing duck, duck, doom. I pray no one dies."
These are the heart-felt words of Joanna, a 50-year-old Californian woman who faces death within a few short weeks if the drug that she takes to keep her alive is not released from FDA-sanctioned recall, and/or offered to patients by the drugmaker through a "special use" program (at the patients' risk).
The troubles began early last month when Japanese drug-maker Takeda Pharmaceutical pulled Natpara, which was
approved four years ago to treat hypoparathyroidism - a rare endocrine disorder that can lead to heart failure and death.
Takeda recalled the product after learning rubber particles may clog needles in multi-dose cartridges that deliver the solution. However, Takeda did not indicate why the rubber particles were suddenly appearing or how long the problem may last.
Meanwhile, as Statnews.com reports, the FDA upped the ante earlier this month by giving the recall a Class 1
designation, which is reserved for products that may cause serious injury or death.
This requires patients to return all products, although the regulator has offered no information about the extent of the problem, confusing patients and physicians.
The move by Takeda and the FDA has left about 2,700 patients without alternatives - the possibility of a painful death awaits absent the recombinant human protein that has no alternative.
more
http://www.zerohedge.com/health/duck-duck-doom-when-big-pharma-decides-who-among-us-worthy-saving?utm_source=feedburner&utm_medium=feed&utm_campaign=Feed%3A+zerohedge%2Ffeed+%28zero+hedge+-+on+a+long+enough+timeline%2C+the+survival+rate+for+everyone+drops+to+zero%29
| 
